email article
A prognostic risk estimator that incorporates genomic data and clinical factors could allow for the elimination of androgen deprivation therapy (ADT) in some men with intermediate- or high-risk prostate cancer following radiation therapy (RT), a researcher reported.
In a retrospective validation study involving nearly 750 men who received dose-escalated RT, those with a combined clinical cell-cycle risk (CCR) score below a cutoff of 2.112 had a 10-year risk of distant metastasis of just 4.1%, regardless of National Comprehensive Cancer Network (NCCN) risk group, while those above the threshold had a 10-year risk of 25.3%, reported Jonathan Tward, MD, PhD, of the University of Utah in Salt Lake City.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad .
Myriad Genetics, Inc.February 12, 2021 GMT
SALT LAKE CITY, Feb. 12, 2021 (GLOBE NEWSWIRE) Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today additional data further validating the prognostic power of its Prolaris® test and its ability to help accurately predict which men with more aggressive prostate cancer will benefit from intensification of therapy and which patients may safely avoid such treatments. This second validation study was presented during an oral presentation at the American Society of Clinical Oncology Genitourinary Cancer Symposium (ASCO-GU) by Jonathan Tward M.D., Ph.D, associate professor in the Department of Radiation Oncology at the University of Utah.
Wes Moore to Leave Robin Hood; New America Hires Chief Transformation Officer philanthropy.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from philanthropy.com Daily Mail and Mail on Sunday newspapers.
Operator
Good morning. My name is Vaishnavi, and I ll be your conference operator for today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics Fourth Quarter and Full Year 2020 Financial Results Conference Call. There will be a question-and-answer session to follow. [Operator Instructions]
I would now like to turn the call over to Mr. Ian Karp, Karyopharm s Senior Vice President, Investor and Public Relations. Please go ahead.
Ian Karp
Senior Vice President, Investor And Public Relations
Thanks so much. And thank you all for joining us on today s conference call to discuss Karyopharm s fourth quarter and full year 2020 financial results and business update. This is Ian Karp. And I m joined today by Dr. Michael Kauffman, our Chief Executive Officer; Mr. Mike Mason, Chief Financial Officer; Mr. John Demaree, Chief Commercial Officer; Dr. Jatin Shah, Chief Medical Officer; and Mr. Stephen Mitchener, Chief Business Officer. On the call today, Michael
Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress Commercial Launch of XPOVIO® (selinexor) In Expanded Multiple Myeloma Indication Fully Underway Following December 18, 2020 FDA Approval XPOVIO Net Product Sales of $20.2 Million for Fourth Quarter 2020 and $76.2 Million for the Year 2020; Total Revenues of $35.1 Million for the Fourth Quarter 2020 and $108.1 Million for the Year 2020 Positive CHMP Opinion for NEXPOVIO® (selinexor) in Penta-Refractory Multiple Myeloma Issued; European Commission Decision Expected by April 2021 Conference Call Scheduled for Today at 8:30 a.m. ET
News provided by
Share this article
Share this article